Therapy & Rehabilitation Template Tool

Free Ketamine Infusion Therapy Consent Form Template

Operational & Compliance DisclaimerDisclaimer: This template is a sample for operational and administrative purposes only. ConsentCollect is a software platform, not a law firm or a healthcare provider. Consult with qualified legal counsel and medical directors to ensure compliance with local regulations before deploying any clinical consent form.
Professional medical consent form template for Ketamine Infusion Therapy
ConsentCollect Logo

Informed Consent for Ketamine Infusion Therapy

Patient Informed Consent Documentation

Patient and Treatment Information

Nature and Purpose of Treatment

Ketamine is an NMDA (N-methyl-D-aspartate) receptor antagonist that has been used globally as an anesthetic agent since 1970. In sub-anesthetic doses (typically 0.5 mg/kg administered intravenously over 40 minutes), ketamine acts through non-classical pathways to stimulate glutamate release, promote synaptogenesis (creation of new neural connections), and increase the expression of brain-derived neurotrophic factor (BDNF). This biological action can produce rapid improvements in patients suffering from treatment-resistant depression, severe anxiety, post-traumatic stress disorder (PTSD), and certain chronic pain conditions. The treatment is typically administered in an outpatient clinic setting under the direct supervision of qualified medical staff who monitor vital signs throughout the infusion.

FDA Off-Label Status Disclosure

Intravenous ketamine is approved by the Food and Drug Administration (FDA) as an anesthetic agent for surgical and diagnostic procedures. However, the FDA has not separately approved intravenous ketamine for the treatment of psychiatric disorders (such as depression, anxiety, or PTSD). Use of intravenous ketamine for these psychiatric conditions is considered 'off-label.' While the FDA-approved nasal spray esketamine (Spravato) is available under a restricted distribution program, your provider has determined that intravenous ketamine is appropriate for your clinical needs. Off-label prescribing is a common and legal medical practice when supported by peer-reviewed clinical evidence.

Post-Treatment Safety and Transportation Contract

Ketamine induces transient changes in coordination, motor skills, and cognitive judgment. MANDATORY CONTRACT: You are strictly prohibited from driving a motor vehicle, operating hazardous machinery, or making major legal or financial decisions for 24 hours following each infusion session. You must arrange for a verified designated driver (such as a relative or friend) to transport you home from the clinic. Commercial transportation (taxis, public rideshare services) is acceptable only if you are accompanied by a companion. If you fail to arrange for transport, your infusion session will be cancelled immediately.

Material Risks and Potential Side Effects

Dissociative effects: Feeling detached from one's body, environment, or thoughts (dissociation), altered perceptions of sight, sound, or time, or feeling transiently confused or floating during the infusion.
Cardiovascular changes: Temporary elevations in blood pressure (systolic and diastolic) and heart rate, which typically resolve within 1 to 2 hours post-infusion. Continuous monitoring is conducted to manage risk.
Psychological distress: Transient anxiety, panic, dysphoria, or worsening of depressive thoughts during the administration process, occasionally requiring pharmacological intervention or session suspension.
Urological toxicity: Long-term or high-frequency ketamine exposure is associated with cystitis (inflammation of the bladder), painful urination, urgency, and bladder damage (ketamine-induced cystitis).
Physiological side effects: Nausea and vomiting during or after the session (prophylactic antiemetics like Zofran are administered as needed), dizziness, blurred vision, headache, or motor incoordination.
Habituation and abuse: Ketamine is a Schedule III controlled substance and carries a risk of abuse, dependence, or tolerance, requiring close clinical tracking of treatment frequency and duration.
Hepatotoxicity: Rare cases of liver enzyme elevations have been reported with long-term, repeated ketamine dosing, requiring periodic liver function panels.
Treatment failure: There is no guarantee that ketamine will improve your symptoms. Approximately 30 to 40 percent of patients do not experience significant relief during the induction phase.

Reasonable Alternatives to Ketamine Therapy

Standard oral antidepressant medications: including SSRIs, SNRIs, tricyclics, or MAOIs, in single or combination therapies.
Esketamine nasal spray (Spravato): an FDA-approved, S-enantiomer formulation of ketamine administered under a restricted REMS program.
Neuromodulation therapies: including Transcranial Magnetic Stimulation (TMS) or Electroconvulsive Therapy (ECT) for severe or treatment-resistant cases.
Evidence-based psychotherapy: such as Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), or psychodynamic counseling.
No treatment: refusing this therapy while continuing standard clinical care. The patient has been informed that untreated severe depression carries risks of worsening symptoms and increased suicidal ideation.

Expected Treatment Benefits

The expected benefits of sub-anesthetic ketamine infusions include rapid reduction in the severity of depressive symptoms, alleviation of treatment-resistant anxiety, reduction in intrusive post-traumatic symptoms, and rapid reduction in suicidal ideation. Unlike oral medications that take several weeks to exhibit therapeutic response, ketamine may produce clinical improvements within hours of the first or second infusion. These benefits are temporary and typically require maintenance sessions or ongoing psychiatric care to sustain clinical gains over time.

Right to Refuse or Withdraw Consent

You have the absolute right to refuse this treatment or withdraw your consent at any point during your care plan, including mid-infusion. Choosing not to proceed with Ketamine therapy will not alter your access to other healthcare services at this clinic, nor will it affect your ongoing therapeutic relationship with your psychiatrist.

Patient Comprehension and Verification

By proceeding, I confirm that I have spent sufficient time reviewing this document and asking questions. I have completed the mandatory video resource modules, passed the teach-back comprehension quiz, and listened to the read-aloud form summaries. I understand the post-session driver contract and verify that a designated driver has been arranged for today's appointment.

Language Access and Interpreter Services

If you require language translation or qualified medical interpreter services, they will be provided to you at no additional cost. Please inform the clinic coordinator prior to executing this consent form.

Copy of Consent Acknowledgment

I acknowledge that I have been offered a signed copy of this informed consent form for my personal medical records.

Informed Consent Authorization

I have read this document or had it read to me. I understand the nature, purpose, benefits, alternatives, and material risks of Ketamine infusion therapy. I accept the safety obligations regarding post-treatment transportation. I voluntarily authorize my clinical team to perform the infusion protocol as described above.

Signatures and Attestations

Document ID: CC-KETAMINE-INFUSION-CONSENT-FORM
POWERED BY CONSENTCOLLECT

Need to print or customize this template?

Download a clean PDF copy or customize it in our Free Consent Builder. No account required.

Looking for a complete clinical workflow?

Standard PDF consent forms still leave your practice exposed to malpractice disputes. If you want verified patient comprehension quizzes, automated signing order tracking, biometric signature seals, and direct Epic/Cerner EHR FHIR R4 integration, then upgrade to our full ConsentCollect App.

Free Document Schema Specifications

Template Classification:Ketamine Infusion Therapy Layout
Target File Format:Printable PDF / HTML Structure
Customization Capability:Fully Editable Text & Checklist Fields
Licensing & Rights:Free Personal & Practice-Wide Use

How to Use the Digital Ketamine Infusion Therapy Consent Template

The Ketamine Infusion Therapy document layout available on this page is a structured administrative schema designed for therapy & rehabilitation practice managers, compliance coordinators, and healthcare operations teams. Comprehensive clinical consent form template for Ketamine infusion therapy, detailing off-label status, NMDA receptor mechanism, dissociative side effects, cystitis risks, and safety contracts.

Using the ConsentCollect Free Builder, administrative staff can import this ketamine infusion therapy schema and configure every field to match their specific facility requirements. The builder supports drag-and-drop field reordering, custom label editing, signature block layout control, and client-side PDF generation, with no coding knowledge required and no account needed.

Once the ketamine infusion therapy layout is finalized, it can be printed as a high-resolution paper document, embedded into a digital patient intake kiosk, or exported as a structured JSON payload for integration into an existing EHR or practice management system. Organizations running the full ConsentCollect App subscription gain access to verified comprehension tracking, automated signing sequence management, biometric signature seals, and FHIR R4 interoperability with Epic and Cerner platforms.

❓ Frequently Asked Questions

How do I import and configure this Ketamine Infusion Therapy document layout in the Free Builder?

Click the "Customize in Free Builder" button on this page. The form schema opens directly in the client-side ConsentCollect Free Builder canvas with all fields, sections, and signature blocks pre-loaded. You can then drag and drop additional fields, relabel any section header, swap placeholder text for your facility name and provider credentials, and rearrange the field order to match your clinic workflow, all without creating an account.

What document structure and field types does this Ketamine Infusion Therapy layout include?

This layout contains 13 structured sections covering patient identification fields, administrative intake data, and signature capture blocks. Practice managers and compliance officers can override any field label or placeholder value inside the builder to match their own intake schema.

Can I use this Ketamine Infusion Therapy template for my Therapy & Rehabilitation practice without a paid subscription?

Yes. The Free Advanced Form Builder is entirely public with no account required. You can open this ketamine infusion therapy layout, edit all fields, and export a print-ready PDF or copy the underlying JSON schema at no cost. A paid ConsentCollect App subscription unlocks additional workflow features such as encrypted transmission, timestamped audit logs, multi-party signing order, and direct FHIR R4 EHR integrations.

Does this page provide clinical, legal, or medical advice about ketamine infusion therapy procedures?

No. This page is an administrative document schema tool hosted by ConsentCollect, a B2B compliance software platform. The form layout is provided for operational and administrative configuration purposes only. ConsentCollect is not a law firm, healthcare provider, or clinical advisory service. Before deploying any consent document to patients, the finished form must be reviewed by your organization's qualified legal counsel and a licensed medical director to confirm compliance with applicable regulations in your jurisdiction.

How do I export, print, or integrate this Ketamine Infusion Therapy form schema into my EHR system?

After editing in the Free Builder, use the Export button to download a high-resolution PDF suitable for physical signature collection. Alternatively, copy the JSON schema payload for use in your own patient intake database or web application. Subscribers to the full ConsentCollect App can push finalized templates directly into Epic or Cerner workflows via a certified FHIR R4 integration layer without any manual re-entry.